InMed Pharmaceuticals Appoints Dr. Ado Mohammed as Chief Medical Officer

VANCOUVER, British Columbia, March 4, 2015 /PRNewswire/ -- InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company specializing in the development of cannabinoid based therapies, today announced that it has appointed former Associate Medical Director of GW Pharmaceuticals, Ado Mohammed, MD, DPM, MFPM, as Chief Medical Officer, effective immediately.  Dr. Mohammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.

As Chief Medical Officer, Dr. Mohammed will join InMed's executive management team and will be directly involved in developing the clinical trial strategy for InMed's lead candidates and product development strategy for the Company's pipeline of cannabinoid based therapies, including its two clinical stage programs, CTI-085 and CTI-091, and the recently initiated program for Epidermolysis bullosa simplex (EBS), INM-750.

"Our recent progress and anticipated advancement of our lead drug candidates have made the creation of the Chief Medical Officer position a corporate priority," commented Craig Schneider, Chief Executive Officer of InMed Pharmaceuticals. "There are very few individuals world-wide who have Dr. Mohammed's level of expertise and direct experience in cannabinoid drug development.  We are very fortunate to have been able to attract such a qualified executive to the InMed team."

Dr. Sazzad Hossain, Chief Scientific Officer, added, "Dr. Mohammed's expertise in regulatory affairs, clinical development and marketing in the cannabinoid based therapies is expected to add immediate value to InMed as we seek to successfully advance our cannabinoid based therapies along the clinical and regulatory pathway."

Dr. Mohammed commented, "Joining InMed at this transformative stage, as the company prepares for clinical development of its lead programs, is the opportunity I'd been seeking to continue my passion for bringing cannabinoid therapies to the market.  I look forward to leveraging my expertise in support of InMed's exciting drug candidates."

Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as Associate Medical Director at GW Pharmaceuticals; a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. He played a leading role in GW Pharmaceuticals' pharmacovigilance team where his responsibilities included handling of the company's drug safety data from both clinical trials and post-marketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (NAFDAC) in the areas of pharmacovigilance, post-marketing surveillance and clinical trials.

Prior to joining GW Pharmaceuticals Dr. Mohammed was with PPD, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Dr. Mohammed also served as Chief Medical Officer/Clinical Director in various public healthcare establishments in Africa from 1996 to November 2010.

Dr. Mohammed received his MD at Ahmadu Bello University, Zaria Nigeria followed by an MSc in Orthopaedics at University College London. Dr. Mohammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com

ON BEHALF OF THE BOARD

"Craig Schneider"
President and CEO

Contact:

InMed Pharmaceuticals Inc.
Craig Schneider 
President and Chief Executive Officer 
T: 604.669.7207
F: 604.683.2506
E: [email protected]

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (Investors)
[email protected] 
212-375-2664

Amy Wheeler (Media)
[email protected] 
646-362-5750

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws.  Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about Dr. Mohammed joining InMed's executive management team; Dr. Mohammed's involvement in developing a clinical trial strategy and product development strategy; the expected value to InMed of Dr. Mohammed's expertise; and the expected fundamental value drivers of the company. In connection with the forward-looking information contained in this news release, InMed has made numerous assumptions, regarding, among other things: Dr. Mohammed's continued willingness and availability to serve on the management team; the need for and efficacy of Dr. Mohammed's role in strategy development; and the continued value of InMed's proprietary platform technology, product pipeline and accelerated development pathway. Although management considers these assumptions to be reasonable, there can be no assurance that such assumptions will prove to be correct.  Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: Dr. Mohammed may no longer be willing or able to serve on the management team; Dr. Mohammed's expertise may not prove to be valuable for strategy development, or he may serve a different role altogether; and InMed's proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.

Related Links

http://www.inmedpharma.com